Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EYPT | US
-0.07
-0.51%
Healthcare
Biotechnology
30/06/2024
24/04/2026
13.77
13.79
14.17
13.54
EyePoint Pharmaceuticals Inc. a pharmaceutical company engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States China and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery including EYP-1901 an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals Inc. in March 2018. EyePoint Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Watertown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.8%1 month
53.8%3 months
71.3%6 months
70.5%-
-
2.59
0.10
0.07
-11.49
6.64
-
-96.53M
736.95M
736.95M
-
-364.52
-
4.10
-60.81
14.75
19.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.79
Range1M
3.51
Range3M
7.05
Rel. volume
0.70
Price X volume
8.43M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | TBPH | Biotechnology | 16.46 | 805.26M | 0.92% | n/a | 24.09% |
| SPRY | SPRY | Biotechnology | 8.29 | 803.65M | -0.12% | n/a | 0.07% |
| Sensei Biotherapeutics Inc | SNSE | Biotechnology | 31.79 | 799.55M | -2.54% | n/a | 9.67% |
| PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 11.7 | 798.99M | -3.78% | n/a | -216.56% |
| Arbutus Biopharma Corporation | ABUS | Biotechnology | 4.2 | 792.88M | -1.18% | n/a | 6.09% |
| Omeros Corporation | OMER | Biotechnology | 13.53 | 784.02M | 0.07% | n/a | -356.63% |
| Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 15.01 | 782.99M | -1.18% | n/a | 3.62% |
| MannKind Corporation | MNKD | Biotechnology | 2.7 | 742.49M | -0.37% | 132.00 | -149.80% |
| Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 3.29 | 731.91M | -4.36% | n/a | 29.02% |
| ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 10.24 | 722.36M | -1.82% | n/a | 0.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.31 | 317.09M | 1.85% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.99 | 277.39M | -0.99% | 13.23 | 0.00% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.9543 | 262.62M | -0.42% | n/a | 268.43% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.49 | 0.53 | Cheaper |
| Ent. to Revenue | 6.64 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.59 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 71.31 | 72.80 | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 736.95M | 3.66B | Emerging |